<DOC>
	<DOC>NCT01526785</DOC>
	<brief_summary>The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (LumizymeÂ®) in Pompe participants.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>A participant might meet all of the following criteria to be eligible for this study. 1. The participant and/or their parent/legal guardian was willing and able to provide signed informed consent. 2. The participant might be at least 1 year of age at the time of informed consent. 3. The participant had a diagnosis of Pompe disease and might have received treatment with 160 L alglucosidase alfa prior to screening. 4. The participant, if female and of childbearing potential, might have a negative pregnancy test (urine betahuman chorionic gonadotropin) at baseline. Note: all female participants of childbearing potential and sexually mature males might agree to use a medically accepted method of contraception throughout the study. A participant who met any of the following criteria were to be excluded from this study. 1. The participant had within the past 3 months received or was currently receiving any investigational product other than 160 L alglucosidase alfa or was currently participating in another clinical treatment study. 2. The participant, in the opinion of the Investigator, was clinically unstable and would not be expected to survive to completion of the 52week treatment period. 3. The participant and/or their parent/legal guardian, in the opinion of the Investigator, was unable to adhere to the requirements of the study.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>